High alkaline phosphatase (ALP) activity was found in the cerebrospinal fluid of a patient with intracranial metastases from adenocarcinoma of the lung. On agarose gel electrophoresis of the major ALP isoenzyme found in the cerebrospinal fluid, its mobility was different from those of the usual serum ALP isoenzymes. This abnormal mobility might be due to the linked glycan phosphatidylinositol anchor in the ALP molecule, as the mobility became the same as that of the common liver type ALP after treatment with phosphatidylinositol specific phospholipase. The immunochemical antigenicity of the cerebrospinal fluid ALP was identical with that of the common serum liver type ALP, but its sugar moiety was similar to the membranous liver-type ALP rather than the serum liver type ALP. 
Alkaline phosphatase (ALP, EC 3.1.3.1) isozymes include liver-type, bone-type, placental-type, intestinal-type, and intestinalvariant. ' Moreover, an increase in ALP activity in the serum is frequently associated with malignant tumours and hepatobiliary or bone diseases. Therefore, ALP activity is commonly used as a laboratory variable that provides useful information for clinical diagnosis.23 As part of the recent progress in the elucidation of the mechanism for the appearance and disappearance of ALP in the blood,4 we reported that the sugar moiety of the ALP molecule is closely associated with this mechanism. 5 Case report A 58 year old man was admitted to hospital for investigation of changes of consciousness. Chest radiographs indicated a coin-sized lesion in the upper lobe of the left lung, and his serum carcinoembryonic antigen (CEA) concentration was 30 5 4ug/l (our reference range below 5 jug/l). Furthermore, he had a stiff neck (a sign of meningitis) and the cerebrospinal fluid CEA concentration was extremely high at 2312-7 ,ug/l. The patient was diagnosed as having intracranial metastasis of alveolar adenocarcinoma on the basis of cytological findings in the cerebrospinal fluid (cells were probably poorly differentiated alveolar adenocarcinoma cells).
Methods
Serum and cerebrospinal fluid samples from the patient were kept at -80°C until use. ALP activity was determined using a Hitachi model-736 autoanalyzer (Hitachi Co. Ltd., Tokyo, Japan) at 37°C using an assay kit (Wako Pure Chemical Industries Co. Ltd., Osaka, Japan) with 9-8 mM 4-nitrophenylphosphate and 0 16 mM MgCl, in 0-81 M diethanolamine-HCl buffer (pH 10-0).
For agarose gel electrophoresis, Gel 8 for ALP isozymes and an ALP high resolution staining kit were obtained from Ciba Coming Diagnostics (Palo Alto, Califomia, USA). Procedures for electrophoresis and ALP staining of the gel plate were performed according to the manufacturers' instructions.
To remove the glycan-phosphatidylinositol (GPI) anchor moiety in the ALP molecule, the ALP sample was treated at room temperature for 3 hours with 0-1 U/ml of phosphatidylinositol specific phospholipase C (PIPLC, EC 3.1.4.10, Funakoshi Pharmaceutical Co., Tokyo, Japan), as reported before.6 The resulting aliquot specimen was used as a sample for the electrophoresis.
To determine ALP antigenicity, the ALP sample (9 pl) was pre-incubated for 1 hour at The sugar chain heterogeneity of the ALP isozymes was isolated by Concavalin A, phytohaemagglutinin E, pea seed agglutinin and wheat germ agglutinin affinity chromatographies according to the method described before. 7 The yields of the enzyme activity from the respective lectin columns were more than 90%.
For determination of molecular size, the enzyme sample was treated for 3 hours with 01 U/ml PIPLC and 01 U/ml neuraminidase. 7 The resulting aliquot was run on 5% polyacrylamide gel with 0-1% sodium dodecyl sulphate (SDS) under non-reducing conditions. The enzyme active band was detected by 5-bromo-3-indolylphosphate ptoluidine salt containing 10 ,uM of Zn(CH3COO), and 1 mM MgCl,.6 The molecular size was estimated from relative mobility using standard molecular size markers (Pharmacia, Uppsala, Sweden).
Results
The serum ALP activity of the patient ranged from 289 to 598 U/1 (our reference range: 80 -287 U/1). ALP activity in the cerebrospinal fluid of this patient ranged from 102-287 U/1, outside the reference range (< 5 U/1) derived from the data obtained in 100 patients with meningitis or other non-neoplastic diseases and calculated using nonparametric statistics.
The figure shows that the ALP isozymes in the patient's cerebrospinal fluid on agarose gel electrophoresis were found at the a2-fl globulin region with a tailing phenomenon. Treatment of cerebrospinal fluid with PIPLC shifted the mobility to that of the common liver type ALP.
In (table) . From its apparent molecular size, the ALP in the patient's cerebrospinal fluid was estimated to be 140 kilodaltons equal to that of human duodenal ALP, and unlike human liver (152) and bone (160) ALP.
Discussion
As the ALP in the cerebrospinal fluid of the present case exhibited abnormal isozyme patterns on agarose gel electrophoresis, the organic origin of the patient's ALP could not be identified by its electrophoretic mobility compared with the control ALP isozyme markers (figure). Following treatment with PIPLC, the ALP from the patient's cerebrospinal fluid returned to normal values and shifted to the common liver type ALP, suggesting that the abnormal ALP on the isozyme pattern was attributable to the existence of a GPI anchor in ALP. This abnormal ALP in the cerebrospinal fluid is thought to be derived from live or necrotising cancer cells which can secrete or liberate the ALP molecules, with the GPI anchor being released directly into the cerebrospinal fluid. It is intriguing to speculate whether phospholipase D, which is usually present in healthy serum,8 might not occur in the cerebrospinal fluid of this patient.
With immunological identification made possible with monoclonal antibodies, it was confirmed that the ALP in the patient's cerebrospinal fluid was liver-type ALP, and the major ALP isozyme estimated by immunoprecipitation was also the same as that in liver. Furthermore, the sugar moiety of ALP from the patient's cerebrospinal fluid, as determined by serial lectin affinity chromatography, was also similar to that of liver tissues (data not shown).
Several tumour associated ALPs have been described. These are particularly found with breast and gastrointestinal carcinomas, but there has been one report of a serum liver type ALP in a patient with malignant schwannoma of a peripheral nerve. 9 The ALP in this was derived from the liver rather than the schwannoma.
The reason for the discrepancy in molecular size between the ALP samples from the patient's cerebrospinal fluid and liver tissues may derive from an alternative processing of ALP with respect to protein or sugar chain concentrations as reported for the tumour associated ALPs expressed ectopically in certain tumours.'0 Murakami et all' reported that liver-type ALP was produced in a patient with meningioma, but they did not find an abnormal ALP value. In addition, we did not find-abnormal ALP values in 100 patients with non-neoplastic intracranial diseases. Taken together, our data suggest that the abnormal ALP found in the cerebrospinal fluid from this patient was liver-type ALP produced by intracranial cancer cells which had metastasised from an alveolar lung adenocarcinoma.
This work was supported in part by a grant from the Ministry of Education, Science and Culture ofJapan. 
